Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316071 | 1.00 | PTGS1 (0.36) | PTGS1KCNH2TSHRTHPO | |
| SCHEMBL6683222 | 0.73 | PTGS1 (0.58) | PTGS1KCNH2TSHRTHPO | |
| SCHEMBL6683218 | 0.73 | PTGS1 (0.58) | PTGS1KCNH2TSHRTHPO | |
| SCHEMBL9516195 | 0.69 | TSHR (0.43) | TSHRTHPO | |
| SCHEMBL6684127 | 0.69 | — | — | |
| SCHEMBL6512974 | 0.69 | HDAC3 (0.30) | — | |
| SCHEMBL29139788 | 0.68 | TSHR (0.34) | TSHRTHPO | |
| SCHEMBL15669343 | 0.67 | PTGS1 (0.50) | PTGS1KCNH2 | |
| SCHEMBL15669344 | 0.67 | PTGS1 (0.50) | PTGS1KCNH2 | |
| SCHEMBL18339356 | 0.67 | PTGS1 (0.40) | PTGS1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004062635-A1 | COMPOSITIONS FOR SKIN LIGHTENING COMPRISING BIS-PANTOYL-CYSTAMINE | DSM IP ASSETS B.V. (NL) | 2004-07-29 | — | — | WO | claimed |
| WO-2004062633-A1 | HAIR CARE COMPOSITIONS COMPRISING BIS - PANTOYL - CYSTAMINE OR A DERIVATIVE THEREOF | DSM IP ASSETS B.V. (NL) | 2004-07-29 | — | — | WO | claimed |
| EP-2117652-B1 | COSMETIC COMPOSITIONS | DSM IP ASSETS BV (NL) | 2013-09-25 | — | — | EP | disclosed |
| EP-2219600-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100105638-A1 | COSMETIC COMPOSITIONS | DSM IP ASSETS B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
| US-20090263340-A1 | COSMETIC COMPOSITIONS | DSM IP ASSETS B.V. (NL) | 2009-10-22 | — | — | US | disclosed |
| WO-2009067095-A1 | TOPICAL COSMETIC SKIN LIGHTENING COMPOSITIONS AND METHODS OF USE THEREOF | STIEFEL LABORATORIES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090041687-A1 | Use of opioid receptor antagonists | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| EP-2010132-A1 | COSMETIC COMPOSITIONS COMPRISING SALICYLIC ACID AND ASCORBIC ACID | DSMIP Assets B.V. (NL) | 2009-01-07 | — | — | EP | disclosed |
| EP-1926490-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSMIP Assets B.V. (NL) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007118605-A1 | COSMETIC COMPOSITIONS COMPRISING SALICYLIC ACID AND ASCORBIC ACID | DSM IP ASSETS B.V. (NL) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007051596-A1 | NOVEL RETINYL BIOTINATES AND USE THEREOF | DSM IP ASSETS B.V. (NL) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007039058-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | WO | disclosed |
| WO-2004062633-A1 | HAIR CARE COMPOSITIONS COMPRISING BIS - PANTOYL - CYSTAMINE OR A DERIVATIVE THEREOF | DSM IP ASSETS B.V. (NL) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004062635-A1 | COMPOSITIONS FOR SKIN LIGHTENING COMPRISING BIS-PANTOYL-CYSTAMINE | DSM IP ASSETS B.V. (NL) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004062633-A1 | HAIR CARE COMPOSITIONS COMPRISING BIS - PANTOYL - CYSTAMINE OR A DERIVATIVE THEREOF | DSM IP ASSETS B.V. (NL) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105638-A1 | COSMETIC COMPOSITIONS | NAMPT, NAPRT, ADH1B | PTGS1 4255/4885KCNH2 2561/4885TSHR 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.